Maximum Daily Dose of Caplyta (Lumateperone)
The maximum recommended daily dose of Caplyta (lumateperone) is 42 mg once daily 1.
Standard Dosing
The FDA-approved dosing for Caplyta is straightforward:
- Standard dose: 42 mg once daily (with or without food)
- No titration required - patients start and remain at the therapeutic dose 1
Dose Reductions Required in Specific Situations
While 42 mg is the maximum, certain clinical scenarios mandate lower doses:
Drug Interactions
- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): Reduce to 10.5 mg once daily 1
- Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin): Reduce to 21 mg once daily 1
Hepatic Impairment
- Moderate hepatic impairment (Child-Pugh B): Reduce to 21 mg once daily 1
- Severe hepatic impairment (Child-Pugh C): Reduce to 21 mg once daily 1
- Mild hepatic impairment requires no adjustment
Important Caveats
Do not exceed 42 mg daily under any circumstances. The available capsule strengths are 42 mg, 21 mg, and 10.5 mg 1. Higher doses have been studied (up to 126 mg in cardiac safety studies) but showed increased adverse effects without additional benefit 1.
Avoid CYP3A4 inducers entirely (e.g., carbamazepine, rifampin) as they significantly reduce lumateperone exposure and may render treatment ineffective 1.
The evidence from dose-response meta-analyses consistently shows that 42 mg provides the optimal balance of efficacy and tolerability for both schizophrenia 2 and bipolar depression 3, with higher doses associated with increased discontinuation due to adverse events without proportional efficacy gains.